-- 周二，原油价格延续涨势，布伦特原油期货价格徘徊在三周高位上方，市场对伊朗提出的新和平方案仍持怀疑态度。 布伦特原油期货合约上涨2.3%，至每桶110.72美元，创下4月7日以来的最高水平。 穆尔班原油4月27日收于每桶104.19美元，截至发稿时已停止交易。 尽管有报道称，德黑兰提出以重新开放霍尔木兹海峡为条件，换取美国解除海上封锁，但德国商业银行的分析师指出，在经历了多次虚假消息后，市场对这类说法“正在失去信心”。 盛宝银行的分析师表示：“美伊和平谈判仍处于僵局，重启谈判的努力陷入停滞。据报道，伊朗周末向美国提出了重新开放霍尔木兹海峡的方案，白宫证实特朗普总统的国家安全团队正在讨论该方案。” 美国主导的封锁对伊朗的实际影响日益显著。 Kpler的数据显示，伊朗石油出口量暴跌70%，从3月份的日均185万桶骤降至仅56.7万桶。 据估计，伊朗的储油设施剩余容量不足22天，这意味着到5月中旬，伊朗将面临高达每日150万桶的强制减产。 周一，两艘与伊朗有关联的超级油轮“蒂法尼”号和“菲尼克斯”号在斯里兰卡附近被美军拦截后，转向东行，远离封锁线，这进一步加剧了供应削减的可能性。 加拿大皇家银行资本市场的策略师指出，展望未来，全球消费者面临“残酷夏季”的可能性越来越大。 RBC分析师警告称，这场已持续三个月的冲突引发了现代史上最大的供应冲击，导致近10亿桶原油和成品油供应中断。 即便外交上取得突破，专家也警告说，基础设施和物流的破坏将导致中东油气产量未来缓慢复苏，从而确保高油价和库存紧张的局面持续存在。
Related Articles
International
U.S. Energy Production Climbs 3% YoY in January, EIA Reports
U.S. primary energy production rose 3% year over year in January to 9.1 quadrillion British thermal units, the U.S. Energy Information Administration said in its Monthly Energy Review released Monday.Total fossil fuels production in January was made up of 46% dry natural gas, 31% crude oil, 12% crude oil and 11% natural gas plant liquids, the EIA reported.Total renewable energy production was composed of 56% biomass, 20% wind, 12% hydroelectric power, 11% solar and 1% geothermal energy, according to the agency.U.S. natural gas plant liquids production was 7% higher in January than in the year-ago month. Dry natural gas production and renewable energy production each climbed 4%. Nuclear electric power production and coal production each increased 2%. Crude oil production rose 1%.
$CLX1$LCOX1$NGV1$UNG$UNL$USO
Asia
CanSino Biologics Widens Loss in Q1
CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.
$HKG:6185$SHA:688185
Japan